Status: ASTN endorsed
No. of Patients Currently Recruited: 0 No. of Patients Required: tbcEdema in larger hemispheric infarction can cause neurological deterioration and death. Intravenous glyburide acts on SUR-1 receptors to reduce edema after ischemic stroke. The hypothesis of the CHARM phase 3 randomised trial is that intravenous glyburide will improve the functional outcome after large hemispheric stroke compared to placebo.